Andon Health Co Ltd

Andon Health maintains a strong liquidity position with a current ratio of 6.7, indicating a significant ability to cover short-term obligations with its current assets. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk.

The company's profitability is reflected in a return on equity (ROE) of 1.89% and a return on assets (ROA) of 1.48%. These figures are below the typical thresholds for high-performing healthcare equipment firms, suggesting that Andon Health may not be generating returns as efficiently as its peers.

Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of detailed segment reporting implies that the company's exposure to specific markets or product lines is not transparent, which could pose a risk to investors seeking diversification.

Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. The absence of a clear growth strategy or specific revenue targets for the current or next fiscal year limits the ability to assess its future performance.

The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the available documents. However, the company's debt-to-equity ratio of 0.18 suggests a relatively conservative capital structure, which may limit its ability to leverage growth opportunities.

Recent events and filings do not provide specific details on strategic initiatives or operational changes. The company's ESG score of 23.71 and a governance score of 57.51 indicate moderate governance practices but poor environmental and social performance, which could affect its reputation and regulatory compliance.

Andon Health Co Ltd (002432.SZ) has been formally classified within the Healthcare economic sector, specifically under the Healthcare Services & Equipment activity. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry-specific benchmarks for healthcare providers and equipment manufacturers. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is now rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment offers investors a baseline for evaluating the security of their equity position against potential dilutive events. Liquidity risk, however, is assessed at a medium level. This designation suggests that while the company maintains operational solvency, there may be moderate constraints or volatility in its ability to meet short-term financial obligations without significant cost or delay. This metric is critical for understanding the firm’s cash flow management and financial flexibility. These updates collectively establish a foundational risk and sector profile for Andon Health. With no current analyst coverage or index membership recorded, these internal assessments serve as primary indicators for stakeholders evaluating the company’s market positioning and financial stability within the broader healthcare landscape.

Free cash flow surged 3,337.1% year-over-year, indicating a dramatic improvement in cash generation capabilities.

Cash conversion ratio of 1.03 outperforms the 0.84 cohort median, reflecting superior operational cash management.

Four-year revenue CAGR of -14.8% indicates a persistent and significant long-term decline in sales.

The company faces high credit risk, suggesting potential difficulties in meeting financial obligations or debt servicing.

Medium liquidity risk flags potential challenges in meeting short-term financial obligations or operational needs.

Capex to revenue ratio of -4.81% is below the cohort median, potentially indicating underinvestment in growth.

Revenue ¥2.59B, −19,8% YoY; Operating income +33,3% YoY.

• ▍Revenue ¥2.59B, −19,8% YoY
• ▍Operating income +33,3% YoY
• ▍Net income +33,3% YoY
• ▍Free cash flow +2 807,5% YoY
• ▍Net margin 64.4%